{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:08:55Z","timestamp":1777504135420,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T00:00:00Z","timestamp":1124755200000},"content-version":"vor","delay-in-days":2457,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Japanese Journal of Cancer Research"],"published-print":{"date-parts":[[1998,12]]},"abstract":"<jats:p>The antitumor effects of FK317, a novel substituted dihydrobenzoxazine, were evaluated using human tumor xenografts (small cell lung cancer, non\u2010small cell lung cancer, stomach cancer, colon cancer, pancreatic cancer, breast cancer, cervical cancer and ovarian cancer). Tumor growth\u2010inhibitory effects and the effective dose\u2010range of FK317 were much stronger and broader, respectively, than those of reference drugs such as mitomycin C, adriamycin, cisplatin, taxol and irinotecan. Furthermore, the body weight decrease and myelosuppression in FK317\u2010treated mice were less than in the animals given any of the reference drugs. To explain this tumor selectivity, the distribution of FK317 was investigated after dosing tumor\u2010bearing mice with the <jats:sup>14<\/jats:sup>C\u2010labelled compound. The concentration of FK317 in tumor tissues was relatively low, and long tumor retention was not observed. However, thin\u2010layer chromatographic separation revealed that the radioactivity in the tumor resided mainly in strongly cytotoxic metabolites, while that in other tissues resided mainly in non\u2010cytotoxic metabolites. These results suggest that FK317 shows strong antitumor activity without side effects, and one reason for this is its specific metabolite pattern. FK317 is now undergoing phase I clinical trials.<\/jats:p>","DOI":"10.1111\/j.1349-7006.1998.tb00528.x","type":"journal-article","created":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T14:31:48Z","timestamp":1124807508000},"page":"1306-1317","source":"Crossref","is-referenced-by-count":22,"title":["FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice"],"prefix":"10.1111","volume":"89","author":[{"given":"Yoshinori","family":"Naoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Inami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Takagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusako","family":"Nishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Manda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.589"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.594"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.600"},{"key":"e_1_2_1_5_2","first-page":"1166","article-title":"Antitumor activity and hematotoxicity of a new, substituted dihydro\u2010benzoxazine, FK973, in mice","volume":"48","author":"Shimomura K.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_6_2","first-page":"78","article-title":"Phase I clinical and pharmacokinetic study of FK973","volume":"9","author":"Majima H.","year":"1990","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00183587","article-title":"Phase I trial of FK973: description of a delayed vascular leak syndrome","volume":"9","author":"Pazdur R.","year":"1991","journal-title":"Invest. New Drugs"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050781"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(80)90235-X"},{"key":"e_1_2_1_10_2","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher B. A.","year":"1981","journal-title":"Cancer Res."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1998.tb03269.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1040760111"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.2307\/3570892"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90303-4"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930150304"},{"key":"e_1_2_1_16_2","first-page":"343","article-title":"Comparison of tumor response in nude mice and in patients","volume":"74","author":"Fiebig H. H.","year":"1984","journal-title":"Behring Inst. Mitt."},{"key":"e_1_2_1_17_2","first-page":"1","article-title":"Human tumor xenografts in the nude mouse and their value as the test models in anticancer drug development","volume":"1","author":"Winograd B.","year":"1987","journal-title":"In Vivo (Athens)"},{"key":"e_1_2_1_18_2","volume-title":"\u201cA Synopsis of Cancer Chemotherapy\u201d","author":"Silver R. T.","year":"1977"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","DOI":"10.1159\/000394374","volume-title":"\u201cChemotherapy of Cancer\u201d","author":"Carter S. K.","year":"1981"},{"key":"e_1_2_1_20_2","first-page":"1354","article-title":"Pharmacology of mitomycin C. I. Toxicity and pathologic effects","volume":"20","author":"Phillips F. S.","year":"1960","journal-title":"Cancer Res."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00293985"},{"key":"e_1_2_1_22_2","first-page":"121","article-title":"Preclinical pharmacology and toxicology of Taxotere (RP56976, NSC628503)","volume":"3","author":"Bissery M. C.","year":"1992","journal-title":"Ann. Oncol."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.50.2.355"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.145.3627.55"},{"key":"e_1_2_1_25_2","first-page":"5638","article-title":"Role of NADPH:cytochrome c reductase and DT\u2010diaphorase in the biotransformation of mitomycin C","volume":"44","author":"Keyes S. R.","year":"1984","journal-title":"Cancer Res."},{"key":"e_1_2_1_26_2","first-page":"335","article-title":"Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue homogenates","volume":"133","author":"Schwartz H. S.","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_27_2","first-page":"250","article-title":"Pharmacology of mitomycin C. III. In vitro metabolism by rat liver","volume":"136","author":"Schwartz H.","year":"1962","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(76)80019-9"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1998.tb00495.x"}],"container-title":["Japanese Journal of Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.1998.tb00528.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.1998.tb00528.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T04:45:54Z","timestamp":1698468354000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.1998.tb00528.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1111\/j.1349-7006.1998.tb00528.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.1998.tb00528.x","archive":["Portico"],"relation":{},"ISSN":["0910-5050"],"issn-type":[{"value":"0910-5050","type":"print"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}